CD8A and myeloid sarcoma: To conclude, this study shows for the first time that the 5-HT7 receptor specifically is upregulated on the surface of CD8+ T cells and CD4+ T cell subpopulations in clinical stable MS patients treated with NTZ for at least 6 months.